[Cavinton in the complex treatment of patients with chronic cerebrovascular insufficiency]
Insights
Cavinton improved neurological function in patients with discirculatory encephalopathy (DE). This treatment significantly reduced the risk of DE progression, transient ischemic attacks, and strokes compared to standard therapy.
Area of Science:
- Neurology
- Pharmacology
Background:
- Discirculatory encephalopathy (DE) is a condition affecting brain function due to impaired blood flow.
- Effective treatment strategies for DE are crucial for improving patient outcomes and preventing neurological deficits.
Purpose of the Study:
- To evaluate the efficacy of Cavinton as an add-on therapy for patients with discirculatory encephalopathy.
- To assess the impact of Cavinton on neurological status, cognitive function, and the risk of cerebrovascular events in DE patients.
Main Methods:
- A clinical study involving 138 patients with DE treated with Cavinton (30 mg/day for 90 days, twice yearly) plus basic therapy.
- A control group of 98 patients received only basic therapy (hypotensive, antithrombotic drugs, glycine).
- Neurological and neuropsychological assessments were conducted at baseline and at 3, 6, and 12 months.
Main Results:
- Patients receiving Cavinton showed significant improvement in neurological syndromes compared to the control group over 12 months.
- Cavinton treatment led to a substantial reduction in the risk of DE progression (relative risk 0.01).
- The risk of transient ischemic attacks and strokes was significantly decreased in the Cavinton group (relative risk 0.14).
Conclusions:
- Complex therapy including Cavinton is effective in managing discirculatory encephalopathy.
- Cavinton demonstrates a significant protective effect against the progression of DE and cerebrovascular events like strokes.
Abstract:
A complex clinical-instrumental study included 138 patients with discirculatory encephalopathy (DE) who received cavinton perorally in dose 30 mg/day during 90 days (2 courses in a year) in addition to the basic therapy (hypotensive and antithrombotic drugs, neuroprotector glycine). A control group comprised 98 patients clinically matched with the main group. They received only basic therapy. Neurological status and results of neuropsychological tests were assessed before treatment and to the end of 3, 6 and 12 months. The improvement of all neurological syndromes studied was seen in the main group to the end of 12 months as compared to controls. The complex treatment using cavinton led to the significant decrease of risk of DE progression, development of transitory ischemic attacks and strokes compared to controls (relative risks were 0,01 and 0,14, respectively).
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Atherosclerosis III: Management
Peripheral Artery Disease IV: Nursing Management
Venous Thrombosis III: Interprofessional Care
Atherosclerosis IV: Nursing Management
Ischemic Stroke l: Introduction

